|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Departments of Medicine, Pathology, and Health
Research and Policy, Division of Oncology, Stanford University Medical
Center, CA.
Diffuse large B-cell lymphoma (DLBCL) is characterized by a marked
degree of morphologic and clinical heterogeneity. Establishment of
parameters that can predict outcome could help to identify patients who
may benefit from risk-adjusted therapies. BCL-6 is a
proto-oncogene commonly implicated in DLBCL pathogenesis. A real-time
reverse transcription-polymerase chain reaction assay was established
for accurate and reproducible determination of BCL-6 mRNA expression.
The method was applied to evaluate the prognostic significance of
BCL-6 expression in DLBCL. BCL-6 mRNA expression was
assessed in tumor specimens obtained at the time of diagnosis from 22 patients with primary DLBCL. All patients were subsequently treated
with anthracycline-based chemotherapy regimens. These patients could be
divided into 2 DLBCL subgroups, one with high BCL-6 gene
expression whose median overall survival (OS) time was 171 months and
the other with low BCL-6 gene expression whose median OS
was 24 months (P = .007). BCL-6 gene
expression also predicted OS in an independent validation set of 39 patients with primary DLBCL (P = .01). BCL-6 protein
expression, assessed by immunohistochemistry, also predicted longer OS
in patients with DLBCL. BCL-6 gene expression was an
independent survival predicting factor in multivariate analysis
together with the elements of the International Prognostic Index (IPI)
(P = .038). By contrast, the aggregate IPI score did not
add further prognostic information to the patients' stratification by
BCL-6 gene expression. High BCL-6 mRNA expression should be
considered a new favorable prognostic factor in DLBCL and should be
used in the stratification and the design of risk-adjusted therapies
for patients with DLBCL.
(Blood. 2001;98:945-951) Diffuse large B-cell lymphomas (DLBCLs) represent
the most frequent type of non-Hodgkin lymphomas (NHL), accounting for
30% to 40% of adult NHL.1 DLBCLs represent a diverse
group of lymphoid neoplasms and encompass heterogeneous clinical,
histologic, immunophenotypic, cytogenetic, and molecular genetic
features.2 However, previous attempts to subclassify these
neoplasms on morphologic grounds have suffered from irreproducibility,
leading to their categorization as one single group in the Revised
European American Lymphoma (REAL) classification.2,3
Chemotherapy has greatly improved the outcome for patients with DLBCL.
However, approximately 50% of patients are not cured by the standard
combination chemotherapy regimens, thus highlighting the need to
determine parameters identifying patients at high risk for standard
therapy failure who may benefit from risk-adjusted therapies. A
clinical indicator of prognosis, the International Prognostic Index
(IPI), has been constructed and successfully used to define prognostic
subgroups in DLBCL.4 The IPI takes into account factors
that are mostly linked to patient characteristics (age, performance
status) and to disease extension and growth (disease stage, lactate
dehydrogenase [LDH] levels, and extent of extranodal
involvement). However, it is clear that differences in clinical
features and in treatment responses of DLBCL are owing to the marked
genetic and molecular heterogeneity that underlies disease
aggressiveness and tumor progression. Several molecular abnormalities,
such as BCL-25-9 and survivin10 expression and p53 mutations,7,11,12 were identified as prognostic
indicators of DLBCL. However, at least in p53 expression, contradictory
results were reported in several studies, probably stemming from
methodological differences.7,11,12 BCL-2 expression was
reported to correlate with reduced disease-free survival
(DFS),6,8,9 but it only predicted reduced overall survival
(OS) for patients with DLBCL in one of the reported
studies.6,8,9
Recently, we evaluated DLBCL gene expression profiling by DNA
micro-array techniques.13 Application of hierarchical
clustering to the gene expression data identified 2 molecularly
distinct forms of DLBCL: germinal center-like DLBCL characterized by
the expression of genes normally expressed in germinal center (GC) B
cells and activated B cell-like DLBCL characterized by the expression of genes normally induced during in vitro activation of B cells. Considerable gene expression heterogeneity was present within each
DLBCL subgroup, and no single gene absolutely correlated in expression
with either of these 2 DLBCL subgroups. These 2 subgroups of DLBCL were
also found to be distinct with respect to the presence of ongoing
mutations of the immunoglobulin genes, with the GC type showing
evidence of ongoing mutations and the activated B-cell type showing
none.14 Patients with the GC and the activated B
cell-like forms of DLBCL were found to have different prognoses The BCL-6 gene is normally expressed in B and
CD4+ T cells within the GC,16 and it controls
GC formation and T-cell-dependent antigen responses.17,18
It is considered one of the hallmarks of the GC and is expressed in NHL
whose origin is from GC B lymphocytes. The BCL-6 gene is
also regarded to be a proto-oncogene by virtue of its recurrent
involvement in chromosomal translocations repeatedly found in
DLBCL.19-22 BCL-6 gene expression may be
deregulated by these translocations23 or by mutations
affecting its 5' nontranslated regulatory region.24
Previous attempts to evaluate the prognostic significance of
BCL-6 rearrangements led to contradictory results; one study
suggested better overall survival in DLBCL with rearranged BCL-6 gene,25 whereas 2 other studies showed
similar outcomes in DLBCL with and without rearranged BCL-6
gene.5,20 However, the effect of BCL-6 gene
expression on DLBCL patient outcome was not studied. The purposes of
this study were to establish a robust method for the measurement of
BCL-6 mRNA expression and to determine the clinical usefulness of
BCL-6 gene expression for predicting OS in DLBCL patients
treated with anthracycline-based chemotherapy at a single institution.
Patient material and cell lines
DLBCL tissues were chosen randomly from a collection of specimens
obtained during the course of diagnostic procedures between 1983 and
1993. Tumor tissues were stored either as fresh-frozen biopsy specimens
embedded in Tissue-Tek Optimal Cutting Temperature (OCT) compound 4583 (Miles, Elkhart, IN) and preserved at Real-time polymerase chain reaction measurement of BCL-6
mRNA expression
For each PCR run, a master mixture was prepared at 4°C with 1×
TaqMan buffer; 5.5 mM MgCl2; 200 mM dATP, dCTP, and dGTP;
400 mM dUTP; 0.01 U/µL AmpErase UNG; and 0.025 U/µL AmpliTaq Gold DNA polymerase (PE Applied Biosystems). The BCL-6 and
GAPDH genes were amplified in the presence of 400 nM BCL-6
primers or 200 nM GAPDH primers (Table
1), which were chosen to hybridize to sequences at the junction between 2 exons or in different exons to
avoid amplification of genomic DNA, and 100 nM appropriate probe (Table
1) labeled with 6-carboxy-fluorescein phosphoramidite (FAM) at the 5'
end and with 6-carboxy-tetramethyl-rhodamine (TAMRA) as quencher at the
3' end. Forty microliters of appropriate master mix were added to 10 µL RT sample. All the real-time quantitative PCR reactions were
performed on an ABI Prism 7700 Sequence Detection System (PE Applied
Biosystems) that captured the fluorescent signal and generated a
real-time amplification plot. Threshold cycle (Ct)
Immunohistochemistry Paraffin blocks were available for 30 study patients. A primary antibody directed against BCL-6 (courtesy of Dr Brunangelo Falini, Department of Hematology, Perugia University, Italy26,27) was used for immunohistochemical staining. Serial sections of 4 µm were cut from paraffin blocks, de-paraffinized in xylene, and hydrated in a graded series of alcohol solutions. This was followed by heat-induced antigen retrieval carried out by microwave pretreatment in EDTA (1 mM, pH 8.0) for 15 minutes before staining. Endogenous peroxidase was blocked by preincubation with 1% hydrogen peroxide in phosphate-buffered saline. Staining detection was carried out using a modified biotin-streptavidin-horseradish peroxidase method.28Staining for BCL-6 was localized predominantly to the nucleus. Staining of lymphoma cells was defined as negative if no staining or staining in less than 10% of lymphoma cells was observed. Staining of lymphoma cells was defined as positive if more than 10% of lymphoma cells stained with the antibody. Two pathologists independently performed interpretation of the immunostaining without knowledge of the real-time RT-PCR results. Statistical analysis Intra-run and inter-run variability was assessed by coefficient of variation (CV) using Excel computer software. OS time of patients with DLBCL was calculated from the date of diagnosis until death or last follow-up examination. DFS was measured as the interval between the date of complete remission after induction treatment and the date of relapse, death, or date of last follow-up evaluation. Survival curves were estimated using the product-limit method of Kaplan-Meier and were compared using the log-rank test. Multivariate regression analysis according to the Cox proportional hazards regression model,29 with OS as the dependent variable, was used to adjust the effect of BCL-6 expression for IPI. P < .05 was considered significant.
BCL-6 gene and internal control primers and probes To assess the expression of the BCL-6 gene, the probe and the primers were designed, which hybridized to sequences between 2 exons to avoid the amplification of genomic DNA. No measurable fluorescence signal was detected in repeated RT-PCR runs in which the reverse transcriptase was omitted from the reaction mixture. Primers were tested by standard endpoint RT-PCR, and the single band obtained was sequenced directly to ensure its origin from the BCL-6 gene (data not shown).To ensure that the quantitation of BCL-6 gene expression in serial samples was not affected by differences in the amount of RNA added, integrity of RNA, or sample-to-sample differences in levels of RT-PCR inhibition, an internal control reaction targeting the GAPDH gene was run with each BCL-6 gene reaction. The GAPDH gene was chosen as an internal control because in our previous experiments using DNA micro-arrays, we found that its expression is constant in a large set of different lymphoma samples. The GAPDH gene has well-characterized primers and TaqMan probe that are commercially available. However, the performance of the GAPDH probe labeled with JOE (2,7-dimethoxy-4,5 dichloro-6 carboxyfluorescin) and supplied by the PE Applied Biosystems was less reproducible than the performance of the same probe labeled with FAM. Therefore, both the BCL-6 and the GAPDH probes were labeled with FAM at the 5' end and with TAMRA as quencher at the 3' end, and the reactions were run side by side and not multiplexed. For each RT-PCR run, standard curves for BCL-6 and
GAPDH gene quantitation were produced by serial 5-fold
dilutions of control human RNA into water and performance of real-time
RT-PCR (Figure 1). Standard curves from
the data collected in triplicate for both BCL-6 and
GAPDH genes reproducibly resulted in correlation coefficients of more than 0.980 for both BCL-6 and
GAPDH genes. The GAPDH values were used to normalize BCL-6
values as described in "Materials and methods."
Reproducibility Reproducibility of the quantitation method was examined by comparing results obtained from replicate samples during the same reaction run (intra-run variability) and on different days (inter-run variability). Intra-run variability analysis was performed on 5-fold dilutions of RNA obtained from the Raji cell line. For this experiment, 6 replicates at each dilution of Raji cell line RNA were amplified. There was little variability in the Ct of the 6 replicates at each dilution of Raji cell line RNA (Table 2). Inter-run variability was assessed by performing real-time RT-PCR on 6 replicates of 20 ng Raji cell RNA on 4 separate days. When the mean Ct of 6 replicate measures from each day are compared, the CV is 1.9%; no pair of results had a difference of more than 0.5 log. We assessed the inter-run variability at 20 ng RNA input because for all our future experiments on tissue samples, we used this RNA amount in each reaction run.
BCL-6 gene expression measurements in non-DLBCL specimens To assess the validity of the method, BCL-6 gene expression was measured in K562 and HL-60 cell lines that previously were shown not to express BCL-6, in GC lymphocytes, and in FCL specimens known to express BCL-6 (Figure 2). Barely detectable levels of BCL-6 were found in the K562 and HL-60 cell lines in agreement with previous evaluations of BCL-6 gene expression by Northern blot analysis. BCL-6 gene expression was detected, as expected, in all GC lymphocyte preparations and in all FCL specimens. A similar range of BCL-6 gene expression was observed in GC cells and in FCL specimens.
BCL-6 gene expression in DLBCL specimens Sixty-one DLBCL specimens were tested for BCL-6 gene expression. Before performance of the real-time RT-PCR, the specimens were randomly divided into 2 sets: the derivation set (22 samples) and the validation set (39 samples). Both sets were similar in their pretreatment clinical characteristics. We divided the specimens in the derivation set into 2 subgroups: DLBCL with high BCL-6 gene expression (greater than 1.3) and DLBCL with low BCL-6 gene expression (equal to or lower than 1.3). The 1.3 cut-off was chosen by permutation analysis of different cut-offs in the derivation set and appeared to coincide with the median BCL-6 expression in Mantle cell lymphomas, which are thought to be BCL-6-negative by less sensitive conventional methods (data not shown). With a median follow-up of 49 months (range, 6-171 months), the OS rate was significantly higher in the DLBCL patients with high BCL-6 gene expression than in the DLBCL patients with low BCL-6 gene expression (median OS of 171 and 24 months, respectively; P = .007 (Figure 3). To validate the power of BCL-6 gene expression in DLBCL for the prediction of OS, we examined BCL-6 gene expression in the validation set of DLBCL (Figure 4). With a median follow-up of 34 months (range, 7-144 months), the OS rate in the validation set was also significantly higher in the DLBCL patients with high BCL-6 gene expression than in the DLBCL patients with low BCL-6 gene expression (median OS of 84 and 22 months, respectively; P = .01) (Figure 4). Because the derivation and the validation sets were similar in all the clinical parameters and in the outcome prediction by BCL-6 mRNA expression, and because the number of examined cases was small, we combined these 2 groups for further analysis.
Complete remission rates in DLBCL groups with high (greater than 1.3)
and low (1.3) BCL-6 gene expression were 74% and 67%, respectively (P > .05). DFS was significantly longer in
DLBCL groups with high (greater than 1.3) rather than low (equal to or
lower than 1.3) BCL-6 gene expression (P = .02)
(Figure 5). Event-free survival was also
significantly longer in DLBCL groups with high (greater than 1.3)
rather than low (equal to or lower than 1.3) BCL-6 gene
expression (P = .03) (data not shown).
Clinical characteristics at presentation were similar in patients with
high (greater than 1.3) and low (equal to or lower than 1.3)
BCL-6 gene expression (Table
3). To determine whether the molecular
definition of DLBCL subgroups by BCL-6 gene expression could
add to the prognostic value of IPI, the OS of patients with high
(greater than 1.3) and low (equal to or lower than 1.3)
BCL-6 gene expression was evaluated separately in patients
with low-low intermediate and high intermediate-high IPI scores.
Because of the small number of patients in each IPI score subgroup, we
combined patients with low or low intermediate (low clinical risk) and high intermediate or high (high clinical risk) scores from both the
derivation and the validation sets. The IPI score in this group of
patients did not predict patient outcome, probably because of the
relatively small number of patients in the group at high clinical risk.
However, considering patients with low clinical risk separately, as
judged by IPI, patients in the high (greater than 1.3) BCL-6
gene expression group had a distinctly better OS than patients with low
(equal to or lower than 1.3) BCL-6 gene expression
(P = .006) (Figure 6). In
patients with high clinical risk, as judged by IPI, the OS was also
significantly longer in patients with high (greater than 1.3)
BCL-6 gene expression (P = .02). Multivariate
regression analysis that included IPI and BCL-6, with OS as the
dependent variable, demonstrated that BCL-6 mRNA expression is an
independent predictor of OS in DLBCL patients (P = .003).
Multivariate regression analysis that included independent components
of the IPI score and the BCL-6, with OS as the dependent variable,
demonstrated that BCL-6 mRNA expression and LDH levels were 2 independent predictors of OS in these DLBCL patients (Table 4).
To further assess the strength of BCL-6 in predicting survival, we fit Cox proportional hazards model with BCL-6 as the predictor. Given that there was one large BCL-6 value (32.5), it was not appropriate to use the exact values in the model. Hence, we converted BCL-6 exact expression values to ranks and used the ranks as the predictor. In univariate and multivariate analyses, including IPI, BCL-6 expression predicted the OS of the DLBCL patients (P = .023 and P = .045, respectively). Correlation with immunohistochemistry BCL-6 protein expression was analyzed by staining with anti-BCL-6 antibody in 30 patients for whom paraffin-embedded samples were available. Scoring was performed without knowledge of the RNA expression results. Specimens were classified as BCL-6-negative or -positive according to the criteria described in "Materials and methods." Nineteen specimens were defined as BCL-6 positive and 11 specimens as BCL-6 negative. The OS of BCL-6-positive cases was significantly better than the OS of the BCL-6-negative cases (median OS of 171 and 40 months, respectively; P = .049) (Figure 7). There were 7 discrepancies in categorization of the samples as BCL-6 positive and negative and as expressing high and low BCL-6 mRNA levels by immunohistochemistry and quantitative real-time PCR, respectively. Absence of concordance between BCL-6 mRNA and protein expression has been previously reported.30 However, similar prediction of better outcome in patients expressing elevated levels of BCL-6 was observed by both methods (Figure 7).
In this study we had 2 aims: to design a specific, reproducible, and robust method for quantitative measurement of BCL-6 gene RNA expression and to evaluate whether BCL-6 gene expression has prognostic significance in DLBCL. The BCL-6 gene, identified by virtue of its involvement in
chromosomal translocations affecting band 3q27, encodes a POZ/Zinc finger sequence-specific transcriptional repressor.31-33
Clonal BCL-6 rearrangements cluster within a highly
conserved 4.0-kb regulatory region spanning the first noncoding exon
containing the promoter and the 5' region of the first intron A simple and precise quantitative method for measurement of
BCL-6 gene expression has not been available. Immunostaining
with anti-BCL-6 antibodies is a semiquantitative method that is
difficult to standardize. Evaluation of the BCL-6 gene
expression by Southern or Western blot analysis requires relatively
large amounts of tumor specimens for RNA and protein extraction,
respectively. In addition, it is difficult to quantify, may require the
use of radioactive materials, and is time consuming and tedious.
Evaluation of large numbers of specimens by these methods in a timely
fashion may be difficult. Real-time quantitative PCR for
BCL-6 gene expression was developed to address the
deficiencies of traditional methods. Real-time quantitative PCR
exploits the 5'-3' nuclease activity associated with Taq DNA
polymerase and uses a nonextendable, fluorogenically labeled
oligonucleotide probe that is target specific.38 During the extension phase of PCR, the reporter dye from the probe is cleaved,
producing a fluorescence signal detected with a charge-coupled device
camera. The amount of fluorescence produced in a reaction is
proportional to the starting target amount during the early phases of
amplification. Real-time RT-PCR for BCL-6 gene expression has several advantages In our previous study, we demonstrated that the differentiation stage of B lymphocyte at which neoplastic transformation occurs defines the biologic behavior and the outcome of DLBCL.13 In that study, GC-like DLBCL, defined by a cluster of genes whose expression pattern was similar to gene expression in GC lymphocytes, had a better OS than the activated B cell-like DLBCL. Considerable gene expression heterogeneity existed within each subgroup, and no single gene in either of these large clusters was absolutely correlated in expression with the DLBCL subgroup taxonomy. In the present study, we wanted to investigate whether the assessment of expression of a single GC-specific gene by an accurate and sensitive method would predict the OS of patients with DLBCL. The BCL-6 gene is a good candidate gene for such a study because its expression is necessary for GC formation17 and is strictly regulated so that it is almost exclusively expressed only in GC lymphocytes or lymphomas originating at the GC differentiation stage.16 Previous studies investigated the prognostic significance of the BCL-6 rearrangements and mutations in DLBCL. Offit et al25 reported a better clinical outcome of patients with BCL-6 gene rearrangements. However, 2 subsequent studies failed to show improved survival in DLBCL patients with BCL-6 gene rearrangements.5,20 Although BCL-6 gene rearrangement may deregulate BCL-6 gene expression,21,23 patients with DLBCL harboring this rearrangement but not expressing BCL-6 have been reported.39,40 The presence of BCL-6 gene mutations also did not affect patients survival in DLBCL.37 In none of these studies was BCL-6 mRNA or protein expression evaluated. In the present study, we evaluated the impact of BCL-6 mRNA expression on DLBCL outcome. Despite the relatively small number of cases evaluated, the study shows that BCL-6 mRNA expression has prognostic significance in patients with DLBCL. BCL-6 mRNA expression in DLBCL tumors with a cut-off of 1.3, as established in the derivation set and cross-validated in the validation set of patients, predicts DLBCL patient overall survival: patients with high (greater than 1.3) BCL-6 gene expression had significantly better overall survival than DLBCL patients with low (equal to or lower than 1.3) BCL-6 gene expression. Moreover, our study demonstrates that the BCL-6 gene expression can further stratify patients with low and high clinical risk, as defined by the IPI, and that it predicts DLBCL subgroups with different OS in each IPI clinical risk subgroup. Moreover, even in a small group of patients with DLBCL in whom IPI score may not predict the outcome, probably because of the small sample size in each IPI category (as shown in our study group), BCL-6 gene expression may accurately stratify patients into good and bad prognostic groups, thus suggesting its high robustness compared to the IPI score. BCL-6 was an independent prognostic factor in multivariate analysis when tested side by side with the IPI score or separately with each of the components of the IPI. In approximately half our patients, we also assessed whether immunohistochemistry using anti-BCL-6 antibody may discriminate between DLBCL patients with different outcomes. Indeed, immunohistochemistry also separated DLBCL tumors according to whether they did or did not express BCL-6 and demonstrated better OS in patients whose tumors expressed BCL-6, thus suggesting their GC origin. The predictive power of each method (immunohistochemistry and real-time RT-PCR) was similar; however, the number of cases analyzed by both methods was small. Real-time RT-PCR is quantitative and robust and is not dependent on the interpretative skills of the person performing the analysis, whereas immunohistochemistry is more widely available but is semiquantitative and may result in inter-observer variation. Future large-scale side-by-side comparisons of both methods will demonstrate whether one method is better than the other in predicting OS of patients with DLBCL. In the present study, we have demonstrated that the expression of a single gene, BCL-6, can predict the outcome of patients with DLBCL. Concomitant analysis of mRNA expression of an additional gene whose expression is characteristic of GC origin, CD10, did not add to the predictive power of BCL-6 mRNA expression (data not shown). Whether BCL-6 gene expression can predict OS for patients with DLBCL as well as or better than multiple gene expression profiling by cDNA micro-arrays is unknown. In our preliminary experiments on a limited number of cases, there was a good correlation between grouping of DLBCL patients into the GC-like DLBCL and the activated B cell-like DLBCL by cDNA micro-arrays and grouping of DLBCL cases into tumors with high and low BCL-6 gene expression by quantitative RT-PCR, respectively (data not shown). Future studies will determine in a side-by-side comparison the predictive power of both methods in the same patients. Examination of the OS and DFS curves (Figures 4-6) in DLBCL groups with high and low BCL-6 gene expression demonstrates that during the first year, the rates of death and relapse are similar in the 2 groups; subsequently, the curves diverge and the outcome are different. Identification of additional prognostic factors that may identify DLBCL patients with different early outcomes may further contribute to the predictive power of BCL-6 gene expression as a prognostic indicator in DLBCL. In summary, in the present study, we demonstrate that BCL-6 mRNA and protein expression are important independent predictors of OS in patients with DLBCL. Further large-scale studies are needed to confirm our findings. Consideration should be given to incorporate BCL-6 gene expression measurement into the design of treatment strategies aimed at improving the outcome of patients with DLBCL by up-front risk-adjusted therapies.
Submitted October 17, 2000; accepted April 4, 2001.
Supported by grants CA33399 and CA34233 from the United States Public Health Service-National Institutes of Health. R.L. is an American Cancer Society Clinical Research Professor.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Ronald Levy, Department of Medicine, Division of Oncology, Rm 1105, Stanford University School of Medicine, Stanford, CA 94305-5151; e-mail: levy{at}stanford.edu.
1. Jaffe ES. Histopathology of the non-Hodgkin's lymphomas and Hodgkin's disease. In: Canellos GP,Listrer TA,Sklar JL, eds. The Lymphomas. Philadelphia, PA: WB Saunders; 1998:77-106.
2.
Harris NL, Jaffe ES, Stein H, et al.
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments].
Blood.
1994;84:1361-1392
3.
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project.
Blood.
1997;89:3909-3918
4.
A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project [see comments].
N Engl J Med.
1993;329:987-994
5.
Kramer MH, Hermans J, Wijburg E, et al.
Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
Blood.
1998;92:3152-3162
6.
Hermine O, Haioun C, Lepage E, et al.
Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma: Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Blood.
1996;87:265-272
7.
Kramer MH, Hermans J, Parker J, et al.
Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.
J Clin Oncol.
1996;14:2131-2138
8.
Hill ME, MacLennan KA, Cunningham DC, et al.
Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.
Blood.
1996;88:1046-1051
9.
Gascoyne RD, Adomat SA, Krajewski S, et al.
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.
Blood.
1997;90:244-251
10.
Adida C, Haioun C, Gaulard P, et al.
Prognostic significance of survivin expression in diffuse large B-cell lymphomas.
Blood.
2000;96:1921-1925
11.
Ichikawa A, Kinoshita T, Watanabe T, et al.
Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.
N Engl J Med.
1997;337:529-534
12.
Koduru PR, Raju K, Vadmal V, et al.
Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma.
Blood.
1997;90:4078-4091 13. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [see comments]. Nature. 2000;403:503-511[CrossRef][Medline] [Order article via Infotrieve].
14.
Lossos IS, Alizadeh AA, Eisen MB, et al.
Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas.
Proc Natl Acad Sci U S A.
2000;97:10209-10213 15. Alizadeh A, Eisen M, Davis R, et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harbor Symp Quant Biol. 1999;64:71-78[CrossRef][Medline] [Order article via Infotrieve].
16.
Cattoretti G, Chang CC, Cechova K, et al.
BCL-6 protein is expressed in germinal-center B cells.
Blood.
1995;86:45-53 17. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16:161-170[CrossRef][Medline] [Order article via Infotrieve].
18.
Dent AL, Hu-Li J, Paul WE, Staudt LM.
T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT-6.
Proc Natl Acad Sci U S A.
1998;95:13823-13828
19.
Ye BH, Lista F, Lo Coco F, et al.
Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma.
Science.
1993;262:747-750
20.
Bastard C, Deweindt C, Kerckaert JP, et al.
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients.
Blood.
1994;83:2423-2427 21. Chaganti SR, Chen W, Parsa N, et al. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer. 1998;23:323-327[CrossRef][Medline] [Order article via Infotrieve]. 22. Kerckaert JP, Deweindt C, Tilly H, Quief S, Lecocq G, Bastard C. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat Genet. 1993;5:66-70[CrossRef][Medline] [Order article via Infotrieve]. 23. Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J. 1995;14:6209-6217[Medline] [Order article via Infotrieve]. 24. Pasqualucci L, Migliazza A, Ye B, Cattoretti G, Chaganti R, Dalla-Favera R. Transcriptional deregulation of mutated BCL-6 alleles in diffuse large cell lymphomas [abstract]. Blood. 1999;94:58.
25.
Offit K, Lo Coco F, Louie DC, et al.
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma [see comments].
N Engl J Med.
1994;331:74-80
26.
Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L.
Bcl-6 protein expression in normal and neoplastic lymphoid tissues.
Ann Oncol.
1997;8:101-104
27.
Falini B, Bigerna B, Pasqualucci L, et al.
Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease.
Blood.
1996;87:465-471 28. Bindl JM, Warnke RA. Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars. Am J Clin Pathol. 1986;85:490-493[Medline] [Order article via Infotrieve]. 29. Cox D. Regression models and life tables (with discussion). J R Stat Soc, B. 1972;34:187-220.
30.
Allman D, Jain A, Dent A, et al.
BCL-6 expression during B-cell activation.
Blood.
1996;87:5257-5268 31. Seyfert VL, Allman D, He Y, Staudt LM. Transcriptional repression by the proto-oncogene BCL-6. Oncogene. 1996;12:2331-2342[Medline] [Order article via Infotrieve].
32.
Harris MB, Chang CC, Berton MT, et al.
Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of epsilon transcription and immunoglobulin E switching.
Mol Cell Biol.
1999;19:7264-7275
33.
Chang CC, Ye BH, Chaganti RS, Dalla-Favera R.
BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.
Proc Natl Acad Sci U S A.
1996;93:6947-6952
34.
Lo Coco F, Ye BH, Lista F, et al.
Rearrangements of the BCL-6 gene in diffuse large cell non-Hodgkin's lymphoma.
Blood.
1994;83:1757-1759
35.
Migliazza A, Martinotti S, Chen W, et al.
Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma.
Proc Natl Acad Sci U S A.
1995;92:12520-12524
36.
Pasqualucci L, Migliazza A, Fracchiolla N, et al.
BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci.
Proc Natl Acad Sci U S A.
1998;95:11816-11821
37.
Capello D, Vitolo U, Pasqualucci L, et al.
Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia.
Blood.
2000;95:651-659
38.
Heid CA, Stevens J, Livak KJ, Williams PM.
Real-time quantitative PCR.
Genome Res.
1996;6:986-994
39.
Otsuki T, Yano T, Clark HM, et al.
Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences.
Blood.
1995;85:2877-2884 40. Skinnider BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol. 1999;30:803-808[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  L. M. Morton, M. P. Purdue, T. Zheng, S. S. Wang, B. Armstrong, Y. Zhang, I. Menashe, N. Chatterjee, S. Davis, Q. Lan, et al. Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1259 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D de Jong, W Xie, A Rosenwald, M Chhanabhai, P Gaulard, W Klapper, A Lee, B Sander, C Thorns, E Campo, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) J. Clin. Pathol., February 1, 2009; 62(2): 128 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy Ann. Onc., November 1, 2008; 19(11): 1921 - 1926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Le Gouill, P. Talmant, C. Touzeau, A. Moreau, R. Garand, N. Juge-Morineau, F. Gaillard, T. Gastinne, N. Milpied, P. Moreau, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement Haematologica, October 1, 2007; 92(10): 1335 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Pollack A Perspective on DNA Microarrays in Pathology Research and Practice Am. J. Pathol., August 1, 2007; 171(2): 375 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nyman, M. Adde, M.-L. Karjalainen-Lindsberg, M. Taskinen, M. Berglund, R.-M. Amini, C. Blomqvist, G. Enblad, and S. Leppa Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Blood, June 1, 2007; 109(11): 4930 - 4935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy Ann. Onc., May 1, 2007; 18(5): 931 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. de Jong, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, A. Lee, B. Sander, C. Thorns, E. Campo, T. Molina, et al. Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications--A Study From the Lunenburg Lymphoma Biomarker Consortium J. Clin. Oncol., March 1, 2007; 25(7): 805 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill, P. Hoskins, R. Klasa, K. J. Savage, T. Shenkier, J. Sutherland, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood, March 1, 2007; 109(5): 1857 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C van Galen, J. J F Muris, J. J Oudejans, W. Vos, C. P E Giroth, G. J Ossenkoppele, A. P Otte, F. M Raaphorst, and C. J L M Meijer Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL J. Clin. Pathol., February 1, 2007; 60(2): 167 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-W. Chen, X.-T. Hu, A. C. Liang, W.-Y. Au, C.-C. So, M. L. Wong, L. Shen, Q. Tao, K.-M. Chu, Y.-L. Kwong, et al. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma Blood, October 1, 2006; 108(7): 2373 - 2383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. van Imhoff, E.-J. G. Boerma, B. van der Holt, E. Schuuring, L. F. Verdonck, H. C. Kluin-Nelemans, and P. M. Kluin Prognostic Impact of Germinal Center-Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 1, 2006; 24(25): 4135 - 4142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Wallace, D. Shen, G. F. Reed, M. Miyanaga, M. Mochizuki, H. N. Sen, S. S. Dahr, R. R. Buggage, R. B. Nussenblatt, and C.-C. Chan Detection of the bcl-2 t(14;18) Translocation and Proto-Oncogene Expression in Primary Intraocular Lymphoma. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 2750 - 2756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kaderali, T. Zander, U. Faigle, J. Wolf, J. L. Schultze, and R. Schrader CASPAR: a hierarchical bayesian approach to predict survival times in cancer from gene expression data Bioinformatics, June 15, 2006; 22(12): 1495 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schenten, A. Egert, M. Pasparakis, and K. Rajewsky M17, a gene specific for germinal center (GC) B cells and a prognostic marker for GC B-cell lymphomas, is dispensable for the GC reaction in mice Blood, June 15, 2006; 107(12): 4849 - 4856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Moskowitz Is it time to stop treating subsets of DLBCL with R-CHOP? Blood, June 1, 2006; 107(11): 4197 - 4198. [Full Text] [PDF]
|
|
|
|
|
|
J. N. Winter, E. A. Weller, S. J. Horning, M. Krajewska, D. Variakojis, T. M. Habermann, R. I. Fisher, P. J. Kurtin, W. R. Macon, M. Chhanabhai, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study Blood, June 1, 2006; 107(11): 4207 - 4213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Oschlies, W. Klapper, M. Zimmermann, M. Krams, H.-H. Wacker, B. Burkhardt, L. Harder, R. Siebert, A. Reiter, and R. Parwaresch Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial Blood, May 15, 2006; 107(10): 4047 - 4052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Batchelor and J. S. Loeffler Primary CNS Lymphoma J. Clin. Oncol., March 10, 2006; 24(8): 1281 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Lossos and D. Morgensztern Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma J. Clin. Oncol., February 20, 2006; 24(6): 995 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Garcia, J.-F. Garcia, L. Maestre, E. Lucas, L. Sanchez-Verde, S. Romero-Chala, M.-A. Piris, and G. Roncador Genetic Immunization: A New Monoclonal Antibody for the Detection of BCL-6 Protein in Paraffin Sections J. Histochem. Cytochem., January 1, 2006; 54(1): 31 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sakane-Ishikawa, S.-i. Nakatsuka, Y. Tomita, S. Fujita, I. Nakamichi, T. Takakuwa, H. Sugiyama, S. Fukuhara, M. Hino, A. Kanamaru, et al. Prognostic Significance of BACH2 Expression in Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group J. Clin. Oncol., November 1, 2005; 23(31): 8012 - 8017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Lossos Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6351 - 6357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A K H Shia, G-G Gan, S Jairaman, and S-C Peh High frequency of germinal centre derivation in diffuse large B cell lymphoma from Asian patients J. Clin. Pathol., September 1, 2005; 58(9): 962 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hoffmann, M. Tiemann, C. Schrader, D. Janssen, E. Wolf, M. Vierbuchen, R. Parwaresch, K. Ernestus, A. Plettenberg, A. Stoehr, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping Blood, September 1, 2005; 106(5): 1762 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Quigley Showing the way: large cell lymphoma Blood, April 1, 2005; 105(7): 2624 - 2624. [Full Text] [PDF]
|
|
|
|
|
|
X. Lu, H. Nechushtan, F. Ding, M. F. Rosado, R. Singal, A. A. Alizadeh, and I. S. Lossos Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas Blood, April 1, 2005; 105(7): 2924 - 2932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Li, X. Wang, R. Y.-L. Yu, B. B. Ding, J. J. Yu, X.-M. Dai, A. Naganuma, E. R. Stanley, and B. H. Ye BCL-6 Negatively Regulates Expression of the NF-{kappa}B1 p105/p50 Subunit J. Immunol., January 1, 2005; 174(1): 205 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Lossos, D. K. Czerwinski, A. A. Alizadeh, M. A. Wechser, R. Tibshirani, D. Botstein, and R. Levy Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes N. Engl. J. Med., April 29, 2004; 350(18): 1828 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Hans, D. D. Weisenburger, T. C. Greiner, R. D. Gascoyne, J. Delabie, G. Ott, H. K. Muller-Hermelink, E. Campo, R. M. Braziel, E. S. Jaffe, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood, January 1, 2004; 103(1): 275 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Z. Ferl, J. M. Timmerman, and O. N. Witte From the Cover: Extending the utility of gene profiling data by bridging microarray platforms PNAS, September 16, 2003; 100(19): 10585 - 10587. [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Braaten, R. A. Betensky, L. de Leval, Y. Okada, F. H. Hochberg, D. N. Louis, N. L. Harris, and T. T. Batchelor BCL-6 Expression Predicts Improved Survival in Patients with Primary Central Nervous System Lymphoma Clin. Cancer Res., March 1, 2003; 9(3): 1063 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Lossos, A. A. Alizadeh, R. Rajapaksa, R. Tibshirani, and R. Levy HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma Blood, January 15, 2003; 101(2): 433 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Colomo, A. Lopez-Guillermo, M. Perales, S. Rives, A. Martinez, F. Bosch, D. Colomer, B. Falini, E. Montserrat, and E. Campo Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma Blood, January 1, 2003; 101(1): 78 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Erban and Z. Tang Case 38-2002 - A 54-Year-Old Man with Hypercalcemia, Renal Dysfunction, and an Enlarged Liver N. Engl. J. Med., December 12, 2002; 347(24): 1952 - 1960. [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, Z. Li, A. Naganuma, and B. H. Ye Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas PNAS, November 12, 2002; 99(23): 15018 - 15023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kurata, Y. Maesako, C. Ueda, M. Nishikori, T. Akasaka, T. Uchiyama, and H. Ohno Characterization of t(3;6)(q27;p21) Breakpoints in B-Cell Non-Hodgkin's Lymphoma and Construction of the Histone H4/BCL6 Fusion Gene, Leading to Altered Expression of Bcl-6 Cancer Res., November 1, 2002; 62(21): 6224 - 6230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T.-L. Tang, D. Dowbenko, A. Jackson, L. Toney, D. A. Lewin, A. L. Dent, and L. A. Lasky The Forkhead Transcription Factor AFX Activates Apoptosis by Induction of the BCL-6 Transcriptional Repressor J. Biol. Chem., April 12, 2002; 277(16): 14255 - 14265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Artiga, A.-I. Saez, C. Romero, M. Sanchez-Beato, M.-S. Mateo, C. Navas, M. Mollejo, and M. A. Piris A Short Mutational Hot Spot in the First Intron of BCL-6 Is Associated with Increased BCL-6 Expression and with Longer Overall Survival in Large B-Cell Lymphomas Am. J. Pathol., April 1, 2002; 160(4): 1371 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ueda, T. Uchiyama, and H. Ohno Immunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high- versus low-level expression of BCL6 mRNA Blood, April 1, 2002; 99(7): 2624 - 2625. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Barrans, I. Carter, R. G. Owen, F. E. Davies, R. D. Patmore, A. P. Haynes, G. J. Morgan, and A. S. Jack Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma Blood, February 15, 2002; 99(4): 1136 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Connors, E. D. Hsi, and F. M. Foss Lymphoma of the Skin Hematology, January 1, 2002; 2002(1): 263 - 282. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
those
with GC-like DLBCLs had significantly better OS times than those with
activated B cell-like DLBCLs.
80° or as frozen viable cell
suspensions in 10% dimethyl sulfoxide in liquid nitrogen. Tumor
tissues chosen for the DLBCL study were from untreated patients with a
diagnosis of primary DLBCL (63 specimens) according to the REAL
classification. Specimens were chosen based on (1) diagnosis of primary
DLBCL; (2) availability of the tissue specimen obtained at diagnosis,
before the initiation of therapy; (3) treatment with an
anthracycline-containing chemotherapy; and (4) follow-up at Stanford
University Hospital and availability of the outcome data. In all
patients chosen for the study, disease dissemination was evaluated
before treatment by physical examination, bone marrow biopsy, and
computed tomography of the chest, abdomen, and pelvis. All patients
were staged according to the Ann Arbor system. IPI score could be
determined for 55 patients. Chosen tissue specimens were reviewed to
confirm the diagnosis according to the REAL classification before RNA
extraction. All the DLBCL tumors had the histologic appearance of
centroblastic large cell lymphomas demonstrating diffuse patterns of
involvement without evidence of residual reactive follicles. Two of the
63 DLBCL specimens were excluded from the study after a review of
patient histories and pathology slides revealed that one of the
patients had a diagnosis of stage 1 FCL 15 years earlier and another
had concomitant Hodgkin lymphoma.
) obtained from 3 tonsils from healthy donors, 23 FCL (
) specimens, 22 DLBCL (
)
specimens from the derivation set, and K562 and HL-60 cell lines
(CL, 
).
